These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 17570567)
1. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Houghton CS; Engelhorn ME; Liu C; Song D; Gregor P; Livingston PO; Orlandi F; Wolchok JD; McCracken J; Houghton AN; Guevara-Patiño JA Vaccine; 2007 Jul; 25(29):5330-42. PubMed ID: 17570567 [TBL] [Abstract][Full Text] [Related]
2. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173 [TBL] [Abstract][Full Text] [Related]
3. Candidate epitope identification using peptide property models: application to cancer immunotherapy. Sung MH; Simon R Methods; 2004 Dec; 34(4):460-7. PubMed ID: 15542372 [TBL] [Abstract][Full Text] [Related]
4. A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Beissbarth T; Tye-Din JA; Smyth GK; Speed TP; Anderson RP Bioinformatics; 2005 Jun; 21 Suppl 1():i29-37. PubMed ID: 15961469 [TBL] [Abstract][Full Text] [Related]
5. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design. Schiewe AJ; Haworth IS J Mol Graph Model; 2007 Oct; 26(3):667-75. PubMed ID: 17493854 [TBL] [Abstract][Full Text] [Related]
6. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Kianizad K; Marshall LA; Grinshtein N; Bernard D; Margl R; Cheng S; Beermann F; Wan Y; Bramson J Cancer Res; 2007 Jul; 67(13):6459-67. PubMed ID: 17616707 [TBL] [Abstract][Full Text] [Related]
7. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm. Chang KY; Suri A; Unanue ER Proteomics; 2007 Feb; 7(3):367-77. PubMed ID: 17211830 [TBL] [Abstract][Full Text] [Related]
8. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338 [TBL] [Abstract][Full Text] [Related]
9. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Seo SH; Jin HT; Park SH; Youn JI; Sung YC Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174 [TBL] [Abstract][Full Text] [Related]
10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
11. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. Hayashi A; Wakita H; Yoshikawa T; Nakanishi T; Tsutsumi Y; Mayumi T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S J Control Release; 2007 Jan; 117(1):11-9. PubMed ID: 17126444 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
13. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578 [TBL] [Abstract][Full Text] [Related]
14. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Vider-Shalit T; Raffaeli S; Louzoun Y Mol Immunol; 2007 Feb; 44(6):1253-61. PubMed ID: 16930710 [TBL] [Abstract][Full Text] [Related]
15. An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection. Guerfali FZ; Ben-Abdallah H; Sghaier RM; Ben-Aissa K; Mkannez G; Attia H; Laouini D Infect Genet Evol; 2009 May; 9(3):344-50. PubMed ID: 18420466 [TBL] [Abstract][Full Text] [Related]
16. Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes. Trujillo JA; Gras S; Twist KA; Croft NP; Channappanavar R; Rossjohn J; Purcell AW; Perlman S J Immunol; 2014 Jun; 192(11):5245-56. PubMed ID: 24795457 [TBL] [Abstract][Full Text] [Related]
17. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
20. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]